Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%. Pretomanid is part of two new treatment regimens with high efficacy and shorter treatment durations recently recommended by the World Health Organization (WHO) as the preferred regimens for most drug-resistant tuberculosis patients. Read more here.
top of page
Recent Posts
See AllJohn Green’s new book Everything is Tuberculosis is scheduled to be published in Spring 2025. The novel laces the experiences of Henry, a...
110
The SIILTIBCY test is now available worldwide through the STOP TB GDF for $1.50 per dose. This novel testing option provides an...
80
The WHO has released the 2024 Global Tuberculosis Report and it places TB as the leading infectious disease killer, surpassing COVID-19....
150
bottom of page
Comments